Abstract
Laboratory services company med fusion, a Texas Oncology and The US Oncology Network preferred laboratory, announced an expansion of its oncology testing services to include the new HemeSEQ portfolio of next-generation sequencing (NGS) profiles covering four hematologic neoplasms: acute myeloid leukemia (AML Profile), chronic lymphocytic leukemia (CLL Profile), diffuse large B-cell lymphoma (DLBCL Profile) and myeloproliferative neoplasms (MPN Profile).
Benchamat1234 / Getty Images
Understanding the pathobiology of hematologic diseases and the effective management of patients with these diseases depends on data from accurate molecular diagnostic tests. To help meet this need, med fusion developed the HemeSEQ profiles which expand its hematologic menu to nearly 100 tests, and incorporate NGS technology to more thoroughly interrogate the genetic basis of a patient’s disease.
“Our ultimate goal at med fusion is to help improve patient care,” said Jon Hart, CEO of med fusion. “We believe the best way to accomplish this is by providing physicians with responsible precision medicine tools that deliver actionable results quickly. Our new hematologic neoplasm profiles exemplify our approach, and we look forward to their contribution to patient care for patients with AML, CLL, DLBCL, and MPN.”